Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413681 | 1.00 | CA12 (0.60) | CA12MEN1KMT2AALDH1A1GAA | |
| SCHEMBL700770 | 1.00 | CA12 (0.60) | CA12MEN1KMT2AALDH1A1GAA | |
| Methoxymethane SCHEMBL28666858 | 0.93 | MAPT (0.56) | CA12MEN1KMT2AALDH1A1GAA | |
| SCHEMBL7900527 | 0.84 | GPR35 (0.53) | CA12MEN1KMT2AALDH1A1GAA | |
| SCHEMBL27963506 | 0.84 | ERN1 (0.49) | CA12MEN1KMT2AALDH1A1GAA | |
| SCHEMBL7900525 | 0.84 | GPR35 (0.53) | CA12MEN1KMT2AALDH1A1GAA | |
| SCHEMBL3073532 | 0.82 | ERN1 (0.47) | CA12MEN1KMT2AALDH1A1GAA | |
| SCHEMBL3073529 | 0.82 | ERN1 (0.47) | CA12MEN1KMT2AALDH1A1GAA | |
| SCHEMBL9388114 | 0.81 | CA12 (0.60) | CA12MEN1KMT2AALDH1A1GAA | |
| SCHEMBL29035946 | 0.81 | CA12 (0.60) | CA12MEN1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869133-B1 | A METHOD FOR PRINTING A FLUID MATERIAL USING A CONTINUOUS JET PRINTING TECHNIQUE AND CURABLE COMPOSITION FOR USE IN SAID METHOD | TNO (NL) | 2009-10-21 | — | — | EP | claimed |
| US-7539006-B2 | Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2009-05-26 | — | — | US | claimed |
| US-20070029529-A1 | Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor | KOMATSU AKIHIKO | 2007-02-08 | — | — | US | claimed |
| US-20040245105-A1 | Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2004-12-09 | — | — | US | claimed |
| EP-1437749-A1 | ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR | Rubycon Corporation (JP) | 2004-07-14 | — | — | EP | claimed |
| US-6287373-B1 | FOR ACOUSTIC INK JET PRINTING | XEROX CORPORATION | 2001-09-11 | — | — | US | claimed |
| US-6187082-B1 | COMPOSITION COMPRISED OF THIOUREA AND INK CARBAMATE, EACH WITH SPECIFIED MELTING POINT AND ACOUSTIC-LOSS VALUE, LIGHTFASTNESS COMPONENT, LIGHTFAST ANTIOXIDANT, COLORANT | XEROX CORPORATION | 2001-02-13 | — | — | US | claimed |
| EP-0277554-B1 | PROCESS FOR THE PREPARATION OF HYDROXYBENZALDOXIME-0-ETHERS | BAYER AG (DE) | 1991-04-17 | — | — | EP | claimed |
| US-4845288-A | Process for the preparation of hydroxybenzaldoxime O-ethers | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-04 | — | — | US | claimed |
| US-4751328-A | CATALYTIC REDUCTION OF NITROBENZALDOXIMES | MITSUI TOATSU CHEMICALS, INC. (JP) | 1988-06-14 | — | — | US | claimed |
| JP-60058949-A | — | — | None | — | — | JP | disclosed |
| JP-60178848-A | — | — | None | — | — | JP | disclosed |
| JP-60178847-A | — | — | None | — | — | JP | disclosed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260053838-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDES AND NUCLEOSIDES FOR TREATING VIRAL INFECTIONS | UNIV EMORY (US) | 2026-02-26 | — | — | US | disclosed |
| US-4659774-A | Support for solid-phase oligonucleotide synthesis | AMERICAN HOECHST CORPORATION (US) | 1987-04-21 | — | — | US | disclosed |
| JP-S60178848-A | PRDUCTION OF AMINOBENZYLAMINE | MITSUI TOATSU CHEM INC | 1985-09-12 | — | — | JP | disclosed |
| JP-S60178847-A | PRODUCTION OF AMINOBENZYLAMINE | MITSUI TOATSU CHEM INC | 1985-09-12 | — | — | JP | disclosed |
| EP-0145486-A2 | Microbiological process | GLAXO GROUP LIMITED (GB) | 1985-06-19 | — | — | EP | disclosed |
| JP-S6058949-A | PRODUCTION OF AMINOBENZYLAMINE | MITSUI TOATSU CHEM INC | 1985-04-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053838-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDES AND NUCLEOSIDES FOR TREATING VIRAL INFECTIONS | DCTD, RNMT, NSUN2 | CA12 3673/4885MEN1 3012/4885KMT2A 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.